Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Mar-Apr;29(2):104517.
doi: 10.1016/j.bjid.2025.104517. Epub 2025 Feb 24.

Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease

Affiliations
Practice Guideline

Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease

Jorge Alberto Cortés et al. Braz J Infect Dis. 2025 Mar-Apr.

Abstract

Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.

Keywords: Antifungal agents; Hematologic neoplasms; Invasive pulmonary aspergillosis; Latin America.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The following authors declared no conflict of interest: DAR, DC, DCN, LCN, CD, SIC, LEC, BLG, AMCR, DLO. The following authors declared conflict of interest: JAC (Pfizer), MCV (Pfizer), RMR (Gilead Sciences, Gador, Pfizer), CAA (Moderna, Merck Sharp & Dohme, GlaxoSmithKline, Becton Dickinson, Pfizer), MN (Pfizer, Merck Sharp & Dohme, Knight Therapeutics), LT (Gador, Gilead Sciences, Knight Therapeutics), DEC (IMMY), EPV (Pfizer), FR (Gador, Gilead Sciences, Knight Therapeutics), PC (Pfizer, Merck Sharp & Dohme), RAR (Pfizer, SteinCares, Merck Sharp & Dohme). With no stated interests identified that could be considered potentially conflicting with the primary interest of this EBCS.

Figures

Fig. 1
Fig. 1
Flowchart for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease. ICD-10, International Classification of Diseases, 10th revision.
Fig. 2
Fig. 2
Flowchart Section 1: Primary antifungal prophylaxis of the patient with oncohematologic disease at high-risk of invasive lung aspergillosis.
Fig. 3
Fig. 3
Section 2 of the flowchart: Diagnosis of the patient with oncohematologic disease with clinical suspicion of invasive lung aspergillosis. CT, Computed Tomography; BAL, Bronchoalveolar Lavage; ICD-10, International Classification of Diseases, 10th revision.
Fig. 4
Fig. 4
Section 3 of the flowchart: Treatment of the patient with oncohematologic disease diagnosed with invasive lung aspergillosis. ICD-10, International Classification of Diseases, 10th revision.

Similar articles

References

    1. Cadena J., Thompson G.R., Patterson T.F. Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin North Am. 2016;30:125–142. 3rd. - PubMed
    1. Pagano L., Akova M., Dimopoulos G., Herbrecht R., Drgona L., Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5–14. - PubMed
    1. Thompson G.R., Young J.H. Aspergillus infections. N Engl J Med. 2021;385:1496–1509. 3rd. - PubMed
    1. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347. - PubMed
    1. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources